{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:24:07Z","timestamp":1759332247173,"version":"3.32.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-B-069"],"award-info":[{"award-number":["2022-I2M-C&T-B-069"]}]},{"name":"Beijing Hope Run Special Fund of Cancer Foundation of China","award":["LC2020A17"],"award-info":[{"award-number":["LC2020A17"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79272-8","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:31:35Z","timestamp":1735583495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril\/valsartan based on FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1038","volume":"14","author":[{"given":"Ning","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haijun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"79272_CR1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJ McMurray","year":"2014","unstructured":"McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. New. Engl. J. Med. 371, 993\u20131004 (2014).","journal-title":"New. Engl. J. Med."},{"key":"79272_CR2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.ijcard.2014.08.032","volume":"176","author":"M Volpe","year":"2014","unstructured":"Volpe, M. Natriuretic peptides and cardio-renal disease. Int. J. Cardiol. 176, 630\u2013639 (2014).","journal-title":"Int. J. Cardiol."},{"key":"79272_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1161\/CIRCULATIONAHA.115.018622","volume":"133","author":"SA Hubers","year":"2016","unstructured":"Hubers, S. A. & Brown, N. J. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 133, 1115\u20131124 (2016).","journal-title":"Circulation"},{"key":"79272_CR4","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ijcard.2021.01.061","volume":"331","author":"C Proudfoot","year":"2021","unstructured":"Proudfoot, C. et al. Real-world effectiveness and safety of sacubitril\/valsartan in heart failure: a systematic review. Int. J. Cardiol. 331, 164\u2013171 (2021).","journal-title":"Int. J. Cardiol."},{"key":"79272_CR5","doi-asserted-by":"crossref","unstructured":"Desai, A. S. et al. ,. Factors associated with noncompletion during the run-in period before randomization and influence on the estimated benefit of LCZ696 in the PARADIGM-HF Trial. Circ-Heart Fail. 9 (2016).","DOI":"10.1161\/CIRCHEARTFAILURE.115.002735"},{"key":"79272_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jchf.2020.06.020","volume":"8","author":"KF Docherty","year":"2020","unstructured":"Docherty, K. F., Vaduganathan, M., Solomon, S. D. & McMurray, J. Sacubitril\/Valsartan: neprilysin inhibition 5 years after Paradigm-HF. JACC-Heart Fail. 8, 800\u2013810 (2020).","journal-title":"JACC-Heart Fail."},{"key":"79272_CR7","doi-asserted-by":"crossref","unstructured":"Heidenreich, P. A. et al. ,. AHA\/ACC\/HFSA Guideline for the management of heart failure: executive summary: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol 79, 1757\u20131780 (2022). (2022).","DOI":"10.1016\/j.jacc.2021.12.011"},{"key":"79272_CR8","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599\u20133726 (2021).","journal-title":"Eur. Heart J."},{"key":"79272_CR9","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","volume":"44","author":"M Vaduganathan","year":"2023","unstructured":"Vaduganathan, M. et al. Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of Paraglide-HF and Paragon-HF. Eur. Heart J. 44, 2982\u20132993 (2023).","journal-title":"Eur. Heart J."},{"key":"79272_CR10","doi-asserted-by":"crossref","unstructured":"Chua, S. K., Lai, W. T., Chen, L. C. & Hung, H. F. The antihypertensive effects and safety of LCZ696 in patients with hypertension: a systemic review and meta-analysis of randomized controlled trials. J. Clin. Med. 10 (2021).","DOI":"10.3390\/jcm10132824"},{"key":"79272_CR11","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ejhf.2191","volume":"23","author":"KS Jering","year":"2021","unstructured":"Jering, K. S. et al. Prospective ARNI vs. ACE inhibitor trial to determine superiority in reducing heart failure events after myocardial infarction (PARADISE-MI): design and baseline characteristics. Eur. J. Heart Fail. 23, 1040\u20131048 (2021).","journal-title":"Eur. J. Heart Fail."},{"key":"79272_CR12","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jchf.2016.12.018","volume":"5","author":"N Luo","year":"2017","unstructured":"Luo, N. et al. Early adoption of sacubitril\/valsartan for patients with heart failure with reduced ejection fraction: insights from get with the guidelines-heart failure (GWTG-HF). JACC-Heart Fail. 5, 305\u2013309 (2017).","journal-title":"JACC-Heart Fail."},{"key":"79272_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s10557-021-07210-1","volume":"36","author":"YS Kim","year":"2022","unstructured":"Kim, Y. S. et al. Five years of sacubitril\/valsartan\u2014A safety analysis of randomized clinical trials and real-world pharmacovigilance. Cardiovasc. Drug Ther. 36, 915\u2013924 (2022).","journal-title":"Cardiovasc. Drug Ther."},{"key":"79272_CR14","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1111\/cns.14195","volume":"29","author":"C Chen","year":"2023","unstructured":"Chen, C., Ding, L., Fu, F. & Xiao, J. Updated insights on dementia-related risk of sacubitril\/valsartan: a real-world pharmacovigilance analysis. CNS Neurosci. Ther. 29, 2548\u20132554 (2023).","journal-title":"CNS Neurosci. Ther."},{"key":"79272_CR15","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese, G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 118, 3272\u20133287 (2023).","journal-title":"Cardiovasc. Res."},{"key":"79272_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bjorl.2014.11.001","volume":"81","author":"MM Gananca","year":"2015","unstructured":"Gananca, M. M. Vestibular disorders in the elderly. Braz J. Otorhinolar. 81, 4\u20135 (2015).","journal-title":"Braz J. Otorhinolar"},{"key":"79272_CR17","doi-asserted-by":"publisher","first-page":"1225786","DOI":"10.3389\/fnagi.2023.1225786","volume":"15","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Investigation of hearing loss in elderly vertigo and dizziness patients in the past 10 years. Front. Aging Neurosci. 15, 1225786 (2023).","journal-title":"Front. Aging Neurosci."},{"key":"79272_CR18","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","volume":"143","author":"SS Virani","year":"2021","unstructured":"Virani, S. S. et al. Heart disease and stroke statistics-2021 update: a report from the American Heart Association. Circulation. 143, e254\u2013e743 (2021).","journal-title":"Circulation"},{"key":"79272_CR19","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","volume":"74","author":"J Tromp","year":"2019","unstructured":"Tromp, J. et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J. Am. Coll. Cardiol. 74, 601\u2013612 (2019).","journal-title":"J. Am. Coll. Cardiol."},{"key":"79272_CR20","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/lio2.252","volume":"4","author":"MY Osoba","year":"2019","unstructured":"Osoba, M. Y., Rao, A. K., Agrawal, S. K. & Lalwani, A. K. Balance and gait in the elderly: a contemporary review. Laryngoscope Invest. 4, 143\u2013153 (2019).","journal-title":"Laryngoscope Invest."},{"key":"79272_CR21","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1097\/AUD.0000000000000825","volume":"41","author":"HG Rizk","year":"2020","unstructured":"Rizk, H. G. et al. Cross-sectional analysis of cognitive dysfunction in patients with vestibular disorders. Ear Hear. 41, 1020\u20131027 (2020).","journal-title":"Ear Hear."},{"key":"79272_CR22","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/VES-2006-16301","volume":"16","author":"DA Hanes","year":"2006","unstructured":"Hanes, D. A. & McCollum, G. Cognitive-vestibular interactions: a review of patient difficulties and possible mechanisms. J. Vestibul Res-Equil. 16, 75\u201391 (2006).","journal-title":"J. Vestibul Res-Equil"},{"key":"79272_CR23","first-page":"115","volume":"144","author":"DG Loughrey","year":"2018","unstructured":"Loughrey, D. G., Kelly, M. E., Kelley, G. A., Brennan, S. & Lawlor, B. A. Association of age-related hearing loss with cognitive function, cognitive impairment, and dementia: a systematic review and meta-analysis. Jama Otolaryngol. 144, 115\u2013126 (2018).","journal-title":"Jama Otolaryngol."},{"key":"79272_CR24","doi-asserted-by":"publisher","first-page":"10493","DOI":"10.1038\/s41598-022-14466-6","volume":"12","author":"M Zheng","year":"2022","unstructured":"Zheng, M. et al. Worsening hearing was associated with higher beta-amyloid and tau burden in age-related hearing loss. Sci. Rep-UK. 12, 10493 (2022).","journal-title":"Sci. Rep-UK"},{"key":"79272_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jacc.2019.11.003","volume":"75","author":"M Vaduganathan","year":"2020","unstructured":"Vaduganathan, M. et al. Prior heart failure hospitalization, clinical outcomes, and response to sacubitril\/valsartan compared with valsartan in HFpEF. J. Am. Coll. Cardiol. 75, 245\u2013254 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"key":"79272_CR26","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/phar.2478","volume":"40","author":"HG Rizk","year":"2020","unstructured":"Rizk, H. G. et al. Drug-induced ototoxicity: a comprehensive review and reference guide. Pharmacotherapy. 40, 1265\u20131275 (2020).","journal-title":"Pharmacotherapy"},{"key":"79272_CR27","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.3389\/fphar.2018.01010","volume":"9","author":"E Courtois","year":"2018","unstructured":"Courtois, E. et al. Propensity score-based approaches in high dimension for pharmacovigilance signal detection: an empirical comparison on the French spontaneous reporting database. Front. Pharmacol. 9, 1010 (2018).","journal-title":"Front. Pharmacol."},{"key":"79272_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/clpt.2014.17","volume":"95","author":"H Fang","year":"2014","unstructured":"Fang, H. et al. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics. Clin. Pharmacol. Ther. 95, 496\u2013498 (2014).","journal-title":"Clin. Pharmacol. Ther."},{"key":"79272_CR29","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14740338.2014.915938","volume":"13","author":"Y Hou","year":"2014","unstructured":"Hou, Y. et al. A comparison of disproportionality analysis methods in national adverse drug reaction databases of China. Expert Opin. Drug Saf. 13, 853\u2013857 (2014).","journal-title":"Expert Opin. Drug Saf."},{"key":"79272_CR30","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","volume":"15","author":"PS Ang","year":"2016","unstructured":"Ang, P. S., Chen, Z., Chan, C. L. & Tai, B. C. Data mining spontaneous adverse drug event reports for safety signals in Singapore\u2014A comparison of three different disproportionality measures. Expert Opin. Drug Saf. 15, 583\u2013590 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"79272_CR31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Noren","year":"2013","unstructured":"Noren, G. N., Hopstadius, J. & Bate, A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat. Methods Med. Res. 22, 57\u201369 (2013).","journal-title":"Stat. Methods Med. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79272-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79272-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T09:09:41Z","timestamp":1735636181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79272-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79272"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79272-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31591"}}